{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:50:19Z","timestamp":1788367819684,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Anti-CD74 antibodies (Abs) have been proposed as a diagnostic biomarker in axial spondyloarthritis (axSpA). The aims of this study were to evaluate the association of these Abs with disease activity parameters in axSpA and to assess their predictive value for tumour necrosis factor inhibitor (TNFi) treatment effectiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients diagnosed with axSpA in the Swiss Clinical Quality Management registry with available biosamples and a measurement of IgA anti-CD74 Abs were included in this cohort study. We used a cut-off of 15 U\/ml to define anti-CD74 Abs elevation. Associations of important disease characteristics with anti-CD4 Abs elevation and anti-CD74 Abs levels were evaluated using logistic and linear regression, respectively. For patients with an available biosample before TNFi initiation, we evaluated drug retention and estimated the hazard ratio of treatment discontinuation depending on anti-CD74 Abs elevation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Elevated IgA anti-CD74 Abs were found in 383\/722 (53%) patients with axSpA and were significantly associated with older age, male sex, and elevated C-reactive protein (CRP). Among 310 patients starting TNFi treatment, no significant difference in drug retention was found between patients with and without elevated anti-CD74 Abs (HR 0.91, 95% CI 0.66 to 1.25). An increased Bath Ankylosing Spondylitis Disease Activity Index was found to be associated with a reduced TNFi retention whereas an elevated CRP was associated with a prolonged retention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although elevated IgA anti-CD74 Abs are associated with CRP elevation, we could not demonstrate an additional value of this biomarker for predicting response to treatment with TNFi beyond CRP measurement.<\/jats:p>\n            <jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td colspan=\"3\">Key Points\u2022 Elevated IgA anti-CD74 antibodies are associated with raised CRP\u2022 Elevated IgA anti-CD74 antibodies are not associated with prolonged TNF inhibitor retention after covariate-adjustment<\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07393-0","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:48:45Z","timestamp":1741592925000},"page":"1589-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5896-2230","authenticated-orcid":false,"given":"Annik","family":"Steimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"G\u00f6tschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Br\u00e4ndli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Grosswiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"7393_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/annrheumdis-2012-202208","volume":"73","author":"NT Baerlecken","year":"2014","unstructured":"Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S et al (2014) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73:1211\u20131214. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202208","journal-title":"Ann Rheum Dis"},{"key":"7393_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/annrheumdis-2012-202177","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J (2014) High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 73:1079\u20131082. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202177","journal-title":"Ann Rheum Dis"},{"key":"7393_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.40175","volume":"69","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J et al (2017) Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheumatol 69:1796\u20131806. https:\/\/doi.org\/10.1002\/art.40175","journal-title":"Arthritis Rheumatol"},{"key":"7393_CR4","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/blood-2005-11-4334","volume":"107","author":"D Starlets","year":"2006","unstructured":"Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L et al (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107:4807\u20134816. https:\/\/doi.org\/10.1182\/blood-2005-11-4334","journal-title":"Blood"},{"key":"7393_CR5","doi-asserted-by":"publisher","unstructured":"Sogkas G, Klose K, Baerlecken N, Schweikhard E, Matthias T, Kniesch K, et al. (2020) CD74 is a T cell antigen in spondyloarthritis. Clin Exp Rheumatol 38:195\u2013202. https:\/\/doi.org\/10.55563\/clinexprheumatol\/lezc69\u00a0","DOI":"10.55563\/clinexprheumatol\/lezc69"},{"key":"7393_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/eji.201948502","volume":"50","author":"TS van Kempen","year":"2020","unstructured":"van Kempen TS, Leijten EFA, Lindenbergh MFS, Nordkamp MO, Driessen C, Lebbink RJ et al (2020) Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis. Eur J Immunol 50:1209\u20131219. https:\/\/doi.org\/10.1002\/eji.201948502","journal-title":"Eur J Immunol"},{"key":"7393_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-018-1535-x","volume":"20","author":"JJ De Winter","year":"2018","unstructured":"De Winter JJ, van de Sande MG, Baerlecken N, Berg I, Ramonda R, van der Heijde D et al (2018) Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. Arthritis Res Ther 20:38. https:\/\/doi.org\/10.1186\/s13075-018-1535-x","journal-title":"Arthritis Res Ther"},{"key":"7393_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.40777","volume":"71","author":"E Riechers","year":"2019","unstructured":"Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B et al (2019) Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71:729\u2013735. https:\/\/doi.org\/10.1002\/art.40777","journal-title":"Arthritis Rheumatol"},{"key":"7393_CR9","first-page":"1127","volume":"38","author":"T Witte","year":"2020","unstructured":"Witte T, K\u00f6hler M, Georgi J, Schweikhard E, Matthias T, Baerlecken N et al (2020) IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. Clin Exp Rheumatol 38:1127\u20131131","journal-title":"Clin Exp Rheumatol"},{"key":"7393_CR10","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1093\/rheumatology\/keaa882","volume":"60","author":"L Do","year":"2021","unstructured":"Do L, Gran\u00e5sen G, Hellman U, Lejon K, Geijer M, Baraliakos X et al (2021) Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study. Rheumatology (Oxford) 60:4085\u20134093. https:\/\/doi.org\/10.1093\/rheumatology\/keaa882","journal-title":"Rheumatology (Oxford)"},{"key":"7393_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.semarthrit.2020.12.002","volume":"51","author":"S Xu","year":"2021","unstructured":"Xu S, Zhang X, Chen Y, Ma Y, Deng J, Gao X et al (2021) Anti-CD74 antibodies in spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 51:7\u201314. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.002","journal-title":"Semin Arthritis Rheum"},{"key":"7393_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/rheumatology\/keac384","volume":"62","author":"AS De Craemer","year":"2023","unstructured":"De Craemer AS, Witte T, Lobaton Ortega T, Hoorens A, De Vos M, Cuvelier C et al (2023) Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation. Rheumatology (Oxford) 62:984\u2013990. https:\/\/doi.org\/10.1093\/rheumatology\/keac384","journal-title":"Rheumatology (Oxford)"},{"key":"7393_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82:19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"7393_CR14","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B et al (2013) Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 65:3096\u20133106. https:\/\/doi.org\/10.1002\/art.38140","journal-title":"Arthritis Rheum"},{"key":"7393_CR15","doi-asserted-by":"publisher","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68 Suppl 2:ii1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018\u00a0","DOI":"10.1136\/ard.2008.104018"},{"key":"7393_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101871","volume":"37","author":"FA van Gaalen","year":"2023","unstructured":"van Gaalen FA, Rudwaleit M (2023) Challenges in the diagnosis of axial spondyloarthritis. Best Pract Res Clin Rheumatol 37. https:\/\/doi.org\/10.1016\/j.berh.2023.101871","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7393_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101858","volume":"37","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, Kiltz U, Kononenko I, Ciurea A (2023) Treatment overview of axial spondyloarthritis in 2023. Best Pract Res Clin Rheumatol 37. https:\/\/doi.org\/10.1016\/j.berh.2023.101858","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7393_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landew\u00e9 R (2014) Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73:1455\u20131461. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205178","journal-title":"Ann Rheum Dis"},{"key":"7393_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/keaa292","volume":"60","author":"MM Abdelaziz","year":"2021","unstructured":"Abdelaziz MM, Gamal RM, Ismail NM, Lafy RA, Hetta HF (2021) Diagnostic value of anti-CD74 antibodies in early and late axial spondyloarthritis and its relationship to disease activity. Rheumatology (Oxford) 60:263\u2013268. https:\/\/doi.org\/10.1093\/rheumatology\/keaa292","journal-title":"Rheumatology (Oxford)"},{"key":"7393_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2021.03.026","volume":"228","author":"N\u015e Ya\u015far Bilge","year":"2021","unstructured":"Ya\u015far Bilge N\u015e, Kalyoncu U, Atag\u00fcnd\u00fcz P, Dalk\u0131l\u0131\u00e7 E, Pehlivan Y, K\u00fc\u00e7\u00fck\u015fahin O et al (2021) Uveitis-related factors in patients with spondyloarthritis: TReasure real-life results. Am J Ophthalmol 228:58\u201364. https:\/\/doi.org\/10.1016\/j.ajo.2021.03.026","journal-title":"Am J Ophthalmol"},{"key":"7393_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023433","volume":"99","author":"CJ Hu","year":"2020","unstructured":"Hu CJ, Li MT, Li X, Peng LY, Zhang SZ, Leng XM et al (2020) CD74 auto-antibodies display little clinical value in Chinese Han population with axial spondyloarthritis. Medicine (Baltimore) 99. https:\/\/doi.org\/10.1097\/md.0000000000023433","journal-title":"Medicine (Baltimore)"},{"key":"7393_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P et al (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77:63\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211544","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07393-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:54:51Z","timestamp":1744455291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7393"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07393-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the ethics committee and has therefore been performed in accordance with the ethical standards laid down in the Declaration of Helsinki. All persons gave their informed consent prior to the inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"AnS is supported by the MLR foundation.AG: None.TW: Honoraria for lectures and consultation from Abbvie, Alfasigma, Amgen, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, UCB. Patent on CD74 autoantibody measurement.AlS: None.JB: None.MJN: Honoraria for lectures and consultation from Abbvie, Janssen, Eli Lilly, Novartis, Pfizer, and UCB.BM: None.SG: None.DK: Honoraria for lectures and consultation from Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi.DD: None.ARR: Honoraria for lectures and consultation from Abbvie, Janssen, MSD, Novartis, Pfizer, UCB.SA: None.OD: None.XB: None.AC: None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}